Connect with us

IIPR Stock: Why You Should be Watching This Cannabis REIT

With more states planning to legalize cannabis soon, is it time to buy with IIPR stock hitting a new 52-week low?
The post IIPR Stock: Why You Should be…

Published

on

Despite explosive industry growth, many marijuana stocks are down this year. But, one cannabis company, Innovative Industrial Properties (NYSE: IIPR), offers a unique way to invest. With IIPR stock down 55% this year, it’s the perfect time to add to your watchlist.

Innovative Industrial Properties is a cannabis REIT. The company buys properties and then rents them to licensed operators. In fact, IIPR was the first public company on the NYSE to provide real estate to cannabis companies.

Although IIPR stock has lost more than half its value this year, the company is expanding quickly. For example, in 2021, it bought 37 new properties.

A shifting opinion on cannabis use is helping the market build momentum. With more states planning to legalize it soon, experts believe it will continue. Is it time to buy with IIPR stock hitting a new 52-week low?

Here are a few reasons to watch Innovative Industrial Properties stock while it’s down.

No. 4 Growing Interest in Cannabis

Over the past few years, the public view of cannabis has changed greatly. For one thing, cannabis-based medicines treat several conditions like seizures or anxiety.

Furthermore, policy changes are creating a better image for the plant. Here are a few facts to illustrate.

  • A 2021 poll from Gallup shows a record 68% of Americans support legal marijuana.
  • A survey from the PEW Research Center shows that 91% of U.S adults support cannabis use.
  • Cannabis sales climbed 30% last year, outpacing coffee giant Starbucks (NYSE: SBUX).

In comparison, in 2003, more than 60% of Americans were against it. And the momentum is expected to speed up in the next few years.

U.S cannabis sales expect to reach $46B by 2026, 91% growth from 2020. Not to mention all 50 states expect to have medical cannabis by 2025.

Currently, 37 states, including Washington D.C, have laws allowing medical cannabis. Additionally, another 18 have fully-legal cannabis. With this in mind, the company is taking full advantage of the booming market.

For example, in the past two years, IIPR has grown its number of properties by 65%. On top of this, it has expanded into two more states, gaining six new tenants.

Most importantly, the company has the formula to continue building momentum.

No. 3 Innovative Industrial Properties Has an Advantage

The cannabis real estate business is not as easy as it may look. For one thing, it can be expensive. You need special lighting and equipment. Not to mention raising funds for the industry is still illegal since federal laws prohibit it.

But, IIPR has a way around it. To explain, the company buys properties with state-licensed operators leasing the buildings.

Then, the cannabis REIT leases back the real estate. As a result, cannabis companies can use the funds to expand and create higher returns in the long run. Moreover, it creates a steady revenue source.

The company generally works with 15- to 20-year initial leases. Before IIPR buys a building, they first make sure it passes all the licensing, zoning and regulatory hurdles.

And lastly, IIPR uses triple-net leases. In this type of lease, tenants are responsible for property costs such as repairs, maintenance and taxes.

No. 2 IIPR Stock Is Down 60% From Its Highs Despite Growth

After gaining over 600% from its pandemic lows, IIPR stock reached an all-time high above $288 per share. But, since then, IIPR stock price has slipped 55%.

At the same time, the company is growing rapidly. Innovative generated $64.5M in the first quarter, a 50% increase from last year. Net income also rose 36%, reaching $34.7M, or 1.32 EPS.

Yet the biggest storyline continues to be the company’s growth rate. The company bought 37 buildings last year and another six in 2022.

Meanwhile, the most recent comes as IIPR buys a property in Texas. The company, Texas Original, is one of the only state-licensed companies operating in Texas. With this in mind, the cannabis company expects to control a large part of the market.

So far, IIPR is doing a great job positioning itself for future growth in big market areas. On top of this, it works with some of the top businesses in the industry.

No. 1 Working With Top Cannabis Companies

IIPR is building a portfolio of top-tier tenants. For example, the company’s top ten clients by investment include:

  • PharmaCann – 12.4%
  • Parallel – 9.6%
  • Ascend Wellness – 9.4%
  • Kings Garden – 7.4%
  • Columbia Care – 7%
  • Trulieve – 6.7%
  • Green Thumb – 5.7%
  • Cresco Labs – 5.7%
  • Holistic Industries – 5.7%
  • Curaleaf – 5.1%

The top ten clients make up 75% of the company’s revenue. Some companies are public, others are private, and all (excluding Kings Garden) are in over five states.

In fact, the cannabis REIT has properties across 19 states, with Pennsylvania, Michigan and Illinois making up the majority. In fourth is California, the largest legal marijuana market in the world.

IIPR Stock Forecast: What to Expect

If you are reading this far, you are about to get to the best part. IIPR stock is also a high-yield dividend stock.

Investors can earn a massive 6.46% yield with IIPR stock currently. After raising the payout this past quarter, IIPR pays a quarterly dividend of $1.75. In other words, you earn $7 annually for holding IIPR stock.

As the cannabis industry continues growing, IIPR is taking advantage. Providing real estate and funding can help stimulate the companies they lease to.

Additionally, investing in cannabis companies often comes with varying earnings and strong competition. IIPR offers another way to invest in the growth. With steady revenue and a generous dividend, IIPR stock is a unique marijuana play.

Between shifting public opinion of cannabis and limited access to capital IIPR stock is a REIT you will want on your watchlist this year. Look for the company to continue riding the cannabis wave as the market builds momentum over the next few years.

The post IIPR Stock: Why You Should be Watching This Cannabis REIT appeared first on Investment U.

Read More

Continue Reading

Uncategorized

Aging at AACR Annual Meeting 2024

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging…

Published

on

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Aging is one of the most prominent journals published by Impact Journals

Credit: Impact Journals

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Aging is one of the most prominent journals published by Impact Journals

Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5-10 at the San Diego Convention Center in San Diego, California. This year, the AACR meeting theme is “Inspiring Science • Fueling Progress • Revolutionizing Care.”

Visit booth #4159 at the AACR Annual Meeting 2024 to connect with members of the Aging team.

About Aging-US:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed and archived by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed CentralWeb of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Aging X
  • Aging Facebook
  • Aging Instagram
  • Aging YouTube
  • Aging LinkedIn
  • Aging SoundCloud
  • Aging Pinterest
  • Aging Reddit

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.


Read More

Continue Reading

Government

Mathematicians use AI to identify emerging COVID-19 variants

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants…

Published

on

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.

Credit: source: https://phil.cdc.gov/Details.aspx?pid=23312

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.

The framework combines dimension reduction techniques and a new explainable clustering algorithm called CLASSIX, developed by mathematicians at The University of Manchester. This enables the quick identification of groups of viral genomes that might present a risk in the future from huge volumes of data.

The study, presented this week in the journal PNAS, could support traditional methods of tracking viral evolution, such as phylogenetic analysis, which currently require extensive manual curation.

Roberto Cahuantzi, a researcher at The University of Manchester and first and corresponding author of the paper, said: “Since the emergence of COVID-19, we have seen multiple waves of new variants, heightened transmissibility, evasion of immune responses, and increased severity of illness.

“Scientists are now intensifying efforts to pinpoint these worrying new variants, such as alpha, delta and omicron, at the earliest stages of their emergence. If we can find a way to do this quickly and efficiently, it will enable us to be more proactive in our response, such as tailored vaccine development and may even enable us to eliminate the variants before they become established.”

Like many other RNA viruses, COVID-19 has a high mutation rate and short time between generations meaning it evolves extremely rapidly. This means identifying new strains that are likely to be problematic in the future requires considerable effort.

Currently, there are almost 16 million sequences available on the GISAID database (the Global Initiative on Sharing All Influenza Data), which provides access to genomic data of influenza viruses.

Mapping the evolution and history of all COVID-19 genomes from this data is currently done using extremely large amounts of computer and human time.

The described method allows automation of such tasks. The researchers processed 5.7 million high-coverage sequences in only one to two days on a standard modern laptop; this would not be possible for existing methods, putting identification of concerning pathogen strains in the hands of more researchers due to reduced resource needs.

Thomas House, Professor of Mathematical Sciences at The University of Manchester, said: “The unprecedented amount of genetic data generated during the pandemic demands improvements to our methods to analyse it thoroughly. The data is continuing to grow rapidly but without showing a benefit to curating this data, there is a risk that it will be removed or deleted.

“We know that human expert time is limited, so our approach should not replace the work of humans all together but work alongside them to enable the job to be done much quicker and free our experts for other vital developments.”

The proposed method works by breaking down genetic sequences of the COVID-19 virus into smaller “words” (called 3-mers) represented as numbers by counting them. Then, it groups similar sequences together based on their word patterns using machine learning techniques.

Stefan Güttel, Professor of Applied Mathematics at the University of Manchester, said: “The clustering algorithm CLASSIX we developed is much less computationally demanding than traditional methods and is fully explainable, meaning that it provides textual and visual explanations of the computed clusters.”

Roberto Cahuantzi added: “Our analysis serves as a proof of concept, demonstrating the potential use of machine learning methods as an alert tool for the early discovery of emerging major variants without relying on the need to generate phylogenies.

“Whilst phylogenetics remains the ‘gold standard’ for understanding the viral ancestry, these machine learning methods can accommodate several orders of magnitude more sequences than the current phylogenetic methods and at a low computational cost.”


Read More

Continue Reading

International

There will soon be one million seats on this popular Amtrak route

“More people are taking the train than ever before,” says Amtrak’s Executive Vice President.

Published

on

While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.

Related: This is what it's like to take a 19-hour train from New York to Chicago

Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.

Veronika Bondarenko captured this photo of New York’s Moynihan Train Hall. 

Veronika Bondarenko

Amtrak launches new routes, promises travelers ‘additional travel options’

Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.

More Travel:

According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.

“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”

Here are some of the other Amtrak changes you can expect to see

Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.

To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.

As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.

The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.

Read More

Continue Reading

Trending